Literature DB >> 10496984

Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.

Y Liu1, S M Stack, S S Lakka, A J Khan, D T Woodley, J S Rao, C N Rao.   

Abstract

Human tissue factor pathway inhibitor-2 (TFPI-2)/matrix-associated serine protease inhibitor (MSPI), a Kunitz-type serine protease inhibitor, inhibits plasmin, trypsin, chymotrypsin, plasma kallikrein, cathepsin G, and factor VIIa-tissue factor complex. The mature protein has a molecular mass of 32-33 kDa, but exists in vivo as two smaller, underglycosylated species of 31 and 27 kDa. TFPI-2/MSPI triplet is synthesized and secreted by a variety of cell types that include epithelial, endothelial, and mesenchymal cells. Because the majority (75-90%) of TFPI-2/MSPI is associated with the extracellular matrix (ECM), we examined which components of the ECM bind TFPI-2/MSPI. We found that TFPI-2/MSPI bound specifically to heparin and dermatan sulfate. Interaction of these two glycosaminoglycans (GAGs) with TFPI-2/MSPI involved one or more common protein domains, as evidenced by cross-competition experiments. However, binding affinity for TFPI-2/MSPI with heparin was 250-300 times greater than that for TFPI-2/MSPI with dermatan sulfate. Binding of TFPI-2/MSPI to GAGs was inhibited by NaCl or arginine but not by glucose, mannose, galactose, 6-aminohexanoic acid, or urea, suggesting that arginine-mediated ionic interactions participate in the GAG binding of TFPI-2/MSPI. This supposition was supported by the observation that only NaCl or arginine could elute the TFPI-2/MSPI protein triplet from an ECM derived from human dermal fibroblasts. Reduced TFPI-2/MSPI did not bind to heparin, suggesting that proper disulfide pairings and conformation are essential for matrix binding. To determine whether heparin modulates the activity of TFPI-2/MSPI, we determined the rate of inhibition of plasmin by the inhibitor with and without heparin and found that TFPI-2/MSPI is more active in the presence of heparin. Collectively, our results demonstrate that conformation-dependent arginine-mediated ionic interactions are responsible for the TFPI-2/MSPI triplet binding to fibroblast ECM, heparin, and dermatan sulfate and that heparin augmented the rate of inhibition of plasmin by TFPI-2/MSPI. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496984     DOI: 10.1006/abbi.1999.1371

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  10 in total

Review 1.  Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain.

Authors:  Hiroshi Shigetomi; Akira Onogi; Hirotaka Kajiwara; Shozo Yoshida; Naoto Furukawa; Shoji Haruta; Yasuhito Tanase; Seiji Kanayama; Taketoshi Noguchi; Yoshihiko Yamada; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Inflamm Res       Date:  2010-05-08       Impact factor: 4.575

2.  Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Meena Gujrati; Ian McCutcheon; Dzung H Dinh; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

3.  Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.

Authors:  Zhigang Tang; Guangyong Geng; Qiang Huang; Geliang Xu; Hejie Hu; Jiong Chen; Jiansheng Li
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

4.  Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro.

Authors:  Moonsuk S Choi; Kalpana Parikh; Ashima Saxena; Nageswararao Chilukuri
Journal:  Eplasty       Date:  2007-12-03

5.  Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients.

Authors:  Feng-Kai Sun; Yu-Chen Fan; Jing Zhao; Feng Zhang; Shuai Gao; Ze-Hua Zhao; Qi Sun; Kai Wang
Journal:  Dig Dis Sci       Date:  2012-10-31       Impact factor: 3.199

6.  TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.

Authors:  Gerald F Davies; Arnie Berg; Spike D L Postnikoff; Heather L Wilson; Terra G Arnason; Anthony Kusalik; Troy A A Harkness
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

7.  Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer.

Authors:  Cheng Xu; Huijun Wang; Hongyu He; Fengyun Zheng; Yating Chen; Jin Zhang; Xiaoyan Lin; Duan Ma; Hongwei Zhang
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

8.  Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.

Authors:  Hongshen Guo; Yifeng Lin; Hongwei Zhang; Juan Liu; Nong Zhang; Yiming Li; Desheng Kong; Qiqun Tang; Duan Ma
Journal:  BMC Mol Biol       Date:  2007-12-03       Impact factor: 2.946

9.  Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro.

Authors:  Moonsuk S Choi; Kalpana Parikh; Ashima Saxena; Nageswararao Chilukuri
Journal:  J Burns Wounds       Date:  2007-07-10

10.  TFPI-2 Protects Against Gram-Negative Bacterial Infection.

Authors:  Mohamad N Ali; Gopinath Kasetty; Malin Elvén; Saud Alyafei; Sandra Jovic; Arne Egesten; Heiko Herwald; Artur Schmidtchen; Praveen Papareddy
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.